A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors

International Journal of Gynecological Cancer

Volumn 15, Issue 6, 2005, Pages 1035-1041

  Penson, Richard T ^a   Campos, S M ^b   Seiden, M V ^a   Krasner, C ^a   Fuller Jr , A F ^a   Goodman, A ^a   Roche, M ^a   Willman, A ^b   Muzikansky, A ^c   Matulonis, U A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NONE

Author keywords

Chemotherapy; Clinical trials; Ovarian cancer

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTADENOCARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; FEVER; HUMAN; LIVER METASTASIS; MIXED MULLERIAN TUMOR; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 30944454652     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00482.x     Document Type: Article

References (20)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-8.
3. Penson RT, Seiden MV. Progress in gynecologic oncology. Oncologist 1999;4:293-8.
4. Hansen SW, Tuxen MK, Sessa C. Gemcitabine in the treatment of ovarian cancer. Ann Oncol 1999;10(Suppl. 1): 51-3.
5. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
6. Friedlander M, Millward MJ, Bell D et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1343-5.
7. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
8. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8.
9. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23(5 Suppl. 10):3-15.
10. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992;10:406-13.
11. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21: 3402-8.
12. Trillet-Lenoir V, Freyer G, Kaemmerlen P et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002;75:903-8.
13. Cannistra SA. Is there a 'best' choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 2002;20:1158-60.
14. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002;29 (1 Suppl. 1):9-10.
15. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
16. Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 1999; 22:450-2.
17. Underhill CR, Parnis FX, Highley MS et al. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1996.
18. Underhill CR, Parnis FX, Highley MS et al. Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anticancer Drugs 2001;12:647-52.
19. Kudelka A, CF V, Edwards C. A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian carcinomas. Proc Am Soc Clin Oncol 1999.
20. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 1997;24(2 Suppl. 7):S7-50-5.